175277-19-7

Usage

Uses

Used in Pharmaceutical Industry:
2-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new drug molecules with potential therapeutic applications.
Used in Chemical Research:
2-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE is used as a reagent in chemical research, particularly in the study of benzoic acid derivatives and their reactions with other chemical groups. Its high reactivity makes it a valuable tool for understanding the properties and behaviors of related compounds.
Used in Industrial Manufacturing:
2-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE is used as a raw material in the production of certain industrial chemicals. Its distinct chemical properties may contribute to the development of new materials with specific applications in various industries.
Note: The exact uses and specific safety measures for 2-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE are often confidential and can vary depending on the specific requirements of a given application.

InChI:InChI=1/C8H7F3N2O2/c9-8(10,11)15-6-4-2-1-3-5(6)7(14)13-12/h1-4H,12H2,(H,13,14)

Upstream product

• 162046-61-9 2-trifluoromethoxy-benzoyl chloride 
• 1979-29-9 2-(trifluoromethoxy)benzoic acid 

Downstream Products

• 1245940-97-9 C₂₄H₂₁F₆N₅O₄ 
• 1245940-98-0 C₂₄H₂₁F₆N₅O₄ 
• 1245940-96-8 2-[({4-Cyclopropyl-5-oxo-3-[2-(trifluoromethoxy)phenyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}acetyl)amino]-2-[3-(trifluoromethyl)phenyl]propanamide 
• 1245940-72-0 {4-Cyclopropyl-5-oxo-3-[2-(trifluoromethoxy)phenyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}acetic acid 
• 1245940-71-9 Methyl {4-cyclopropyl-5-oxo-3-[2-(trifluoromethoxy)phenyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}acetate 
• 1245940-70-8 4-Cyclopropyl-5-[2-(trifluoromethoxy)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1245940-69-5 N-Cyclopropyl-2-{[2-(trifluoromethoxy)phenyl]carbonyl}hydrazinecarboxamide 

Relevant academic research and scientific papers

Synthesis of benzoyl hydrazones having 4-hydroxy-3,5-dimethoxy phenyl ring, their biological activities, and molecular modeling studies on enzyme inhibition activities

Hydrazone compounds have high capacity in terms of antioxidant activity and enzyme inhibition activities such as anticholinesterase, tyrosinase, and urease. In this study, benzoyl hydrazones compounds (7a-7m) were synthesized starting from 3,5-dimethoxy-4

From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs

The orexin system is responsible for regulating the sleep-wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we report the optimization efforts toward a DORA, where our starting point was (5-methoxy-4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}methanone (6), a compound which emerged from our in-house research program. Compound 6 was shown to be a potent, brain-penetrating DORA with in vivo efficacy similar to suvorexant in rats. However, shortcomings from low metabolic stability, high plasma protein binding (PPB), low brain free fraction (fu brain), and low aqueous solubility, were identified and hence, compound 6 was not an ideal candidate for further development. Our optimization efforts addressing the above-mentioned shortcomings resulted in the identification of (4-chloro-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1,2,4]triazol-3-yl]-pyrrolidin-1-yl}l-methanone (42), a DORA with improved in vivo efficacy compared to 6.

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to